A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment. (November 2020)

• Record Type: Journal Article
• Authors: Ninomiya, Hiroshi; Ozeki, Michio; Matsuzawa, Yoriko; Nozawa, Akifumi; Yasue, Shiho; Kubota, Kazuo; Endo, Saori; Asano, Takahiko; Taguchi, Kohtaro; Ohe, Naoyuki; Matsuo, Masayuki; Iwama, Toru; Ohnishi, Hidenori
• Is Part Of: Journal of clinical neuroscience. Volume 81(2020)
• Page Start: 431
• Page End: 433
• Publication Date: 2020-11
• Subjects: Brain neoplasms -- Glioma -- Glioblastoma -- Temozolomide; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2020.10.009
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: This is the first report to assess serum VEGF-121 levels in gliomatosis cerebri (GC). A peak serum VEGF121 level of the patient with GC immediately before the treatment was extremely high. VEGF-121 expression declined after treatment in a patient with GC. Abstract: Gliomatosis cerebri (GC) is a rare diffusely infiltrating glial neoplasm that carries a poor prognosis. Because tumors are undetectable in most patients at early-stage of the onset, a useful diagnostic method is expected. We compared serum vascular endothelial growth factor (VEGF)-121 levels in patients with GC or glioblastoma and controls. VEGF-121 levels were significantly higher in one patient with GC and patients with glioblastoma than in controls. VEGF-121 levels decreased in a patient with GC after bevacizumab-based therapy. Thus, VEGF-121 may be useful for diagnosing GC, its disease-monitoring and understanding its etiology.